PARP1 and cancer: Clinically approved PARP inhibitors have been shown to be effective against pancreatic, ovarian, prostate, breast, and other cancers, and although they provide significant benefits compared with standard chemotherapy, clinically approved PARP inhibitors have shown numerous adverse reactions [102].